Last reviewed · How we verify
GSK4428859A
At a glance
| Generic name | GSK4428859A |
|---|---|
| Also known as | belrestotug, EOS884448 |
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors (PHASE1)
- A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer (PHASE2)
- Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid Tumors (PHASE1)
- A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC) (PHASE3)
- Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) (PHASE2)
- Study of Novel Regimens in Relapsed or Refractory Multiple Myeloma (PHASE1)
- Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GSK4428859A CI brief — competitive landscape report
- GSK4428859A updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI